Changing R&D models in research-based pharmaceutical companies

2014 FDA drug approvals

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

2013 FDA drug approvals

(2014) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Grants4Targets: an open innovation initiative to foster drug discovery collaborations

(2014) Heidrun Dorsch et al.   NATURE REVIEWS DRUG DISCOVERY

A decade of innovation in pharmaceutical R&D: the Chorus model

(2014) Paul K. Owens et al.   NATURE REVIEWS DRUG DISCOVERY

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

(2014) David Cook et al.   NATURE REVIEWS DRUG DISCOVERY

The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times

(2014) Joseph A. DiMasi et al.   Therapeutic Innovation & Regulatory Science

Models for open innovation in the pharmaceutical industry

(2013) Alexander Schuhmacher et al.   DRUG DISCOVERY TODAY

2012 FDA drug approvals

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Novelty in the target landscape of the pharmaceutical industry

(2013) Pankaj Agarwal et al.   NATURE REVIEWS DRUG DISCOVERY

Phase II and Phase III attrition rates 2011–2012

(2013) John Arrowsmith et al.   NATURE REVIEWS DRUG DISCOVERY

Four disruptive strategies for removing drug discovery bottlenecks

(2012) Sean Ekins et al.   DRUG DISCOVERY TODAY

Mergers and innovation in the pharmaceutical industry

(2012) William S. Comanor et al.   JOURNAL OF HEALTH ECONOMICS

GlaxoSmithKline opens the door on clinical data sharing

(2012) Charlotte Harrison   NATURE REVIEWS DRUG DISCOVERY

2011 FDA drug approvals

(2012) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Outlook for the next 5 years in drug innovation

(2012) Roy Berggren et al.   NATURE REVIEWS DRUG DISCOVERY

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Pfizer reaches out to academia—again

(2011) Mark Ratner   NATURE BIOTECHNOLOGY

Biotechs follow big pharma lead back into academia

(2011) Jim Kling   NATURE BIOTECHNOLOGY

2010 FDA drug approvals

(2011) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

US academic drug discovery

(2011) Stephen Frye et al.   NATURE REVIEWS DRUG DISCOVERY

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

The impact of mergers on pharmaceutical R&D

(2011) John L. LaMattina   NATURE REVIEWS DRUG DISCOVERY

The productivity crisis in pharmaceutical R&D

(2011) Fabio Pammolli et al.   NATURE REVIEWS DRUG DISCOVERY

Believe it or not: how much can we rely on published data on potential drug targets?

(2011) Florian Prinz et al.   NATURE REVIEWS DRUG DISCOVERY

Can Open-Source Drug R&D Repower Pharmaceutical Innovation?

(2010) B Munos   CLINICAL PHARMACOLOGY & THERAPEUTICS

Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

(2010) J A DiMasi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009

(2010) K I Kaitin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Grants4Targets – an innovative approach to translate ideas from basic research into novel drugs

(2010) Monika Lessl et al.   DRUG DISCOVERY TODAY

Outsourcing lead optimization: the eye of the storm

(2010) David E. Clark   DRUG DISCOVERY TODAY

Pharma embraces open source models

(2010) Stephen Strauss   NATURE BIOTECHNOLOGY

The case for entrepreneurship in R&D in the pharmaceutical industry

(2010) Frank L. Douglas et al.   NATURE REVIEWS DRUG DISCOVERY

Lessons from 60 years of pharmaceutical innovation

(2009) Bernard Munos   NATURE REVIEWS DRUG DISCOVERY

Drug discovery: new models for industry–academic partnerships

(2008) Cathy J. Tralau-Stewart et al.   DRUG DISCOVERY TODAY